Show simple item record

AuthorAl-Jighefee, Hadeel
AuthorNajjar, Hoda
AuthorAhmed, Muna
AuthorQush, Abeer
AuthorAwwad, Sara
AuthorKamareddine, Layla
Available date2021-10-26T08:03:47Z
Publication Date2021
Publication NameVaccines
Identifierhttp://dx.doi.org/10.3390/vaccines9101196
CitationAl-Jighefee, H.T.; Najjar, H.; Ahmed, M.N.; Qush, A.; Awwad, S.; Kamareddine, L. COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. Vaccines 2021, 9, 1196. https://doi.org/10.3390/vaccines9101196
URIhttp://hdl.handle.net/10576/24699
AbstractThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt the pandemic and alleviate its impact on society, economy, and public health, the development of vaccines and antiviral agents against SARS-CoV-2 was a dire need. To date, various platforms have been utilized for SARSCoV-2 vaccine development, and over 200 vaccine candidates have been produced, many of which have obtained the United States Food and Drug Administration (FDA) approval for emergency use. Despite this successful development and licensure, concerns regarding the safety and efficacy of these vaccines have arisen, given the unprecedented speed of vaccine development and the newly emerging SARS-CoV-2 strains and variants. In this review, we summarize the different platforms used for Coronavirus Disease 2019 (COVID-19) vaccine development, discuss their strengths and limitations, and highlight the major safety concerns and potential risks associated with each vaccine type.
Languageen
PublisherMDPI
SubjectSARS-CoV-2
COVID-19
vaccine platforms
challenges
safety
strengths
limitations
TitleCOVID-19 Vaccine Platforms: Challenges and Safety Contemplations
TypeArticle Review
Issue Number10
Volume Number9
ESSN2076-393X
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record